Presentation on theme: "The evolution of generic medicine market share in the pharmaceutical retail sector of 21 countries between 1999 and 2009: a time series analysis Presented."— Presentation transcript:
The evolution of generic medicine market share in the pharmaceutical retail sector of 21 countries between 1999 and 2009: a time series analysis Presented by: Warren A. Kaplan 1 Co-authors: Veronika J. Wirtz 2, Dennis Ross-Degnan 3, Peter Stephens 4 1 Center for Global Health & Development, Boston University, USA 2 Center for Health Systems Research, National Institute of Public Health, Mexico 3 Harvard Medical School and Harvard Pilgrim Health Care Institute 4 IMS Health, UK
Objectives 1.Investigate the retail, private sector market share by volume of generic medicines in various countries since 1999, data provided by IMS-Health. –GLOBALLY, aggregated by regions; –REGIONALLY: Latin America/Caribbean, Asia and Africa –COUNTRY-SPECIFIC-selected countries 2.Investigate the retail, private sectormarket share by volume of selected tracer medicines since 2000, data provided by IMS-Health. –AS INDIVIDUAL TRACER MEDICINES: simvastatin, omeprazole 3.Determine which level of analysis (global, regional, country, and/or tracer) best might provide retrospective and/or prospective data for decision-makers to evaluate existing and future pro-generic medicine policies.
Methods Data obtained from IMS Health PRIVATE SECTOR RETAIL volume data (i.e. number of pills/units)-excluding vitamins and insulin –Latin America/Caribbean: Argentina, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Mexico, Peru, Uruguay, Venezuela, –Asia/Pacific: Bangladesh, Pakistan, Philippines, Thailand, –Africa: Morocco, Tunisia, Egypt, Jordan, South Africa –United States Branded Generic: Brand names marketed by a company without permission (license) from the originator INN generic: Sold by any company under the INN name Generic(s): Branded + INN generics Total Market: Branded + INN+ Originator
Overall, market share of generics has increased; More in LAC than other places
By region, branded generic and INN generic market shares are divergent
In selected Countries: Generic market share is increasing over time but at varying rates
Generic Simvastatin 20mg: Effect of patent expiration U.S. (First patent expired 12/2005) Worldwide: (First patent would have expired in 2001)
Generic Simvastatin 20mg : Even assuming a patent in Jordan/Egypt, why no uptake after 2001?
Omeprazole patent expired in Mexico in 1999 & in the U.S.A. in 2001/NOT patented in other listed countries What is holding back uptake in Mexico? Why the lag in the Philippines?
Conclusions In general, global volume share of generic medicines has increased over the last decade; substantial differences exist by country and region in total generic marked share as well as branded vs. unbranded generics; The large increase in generic market share in LAC might be a result of more comprehensive pro-generic policies; Retail volume and patent data for individual medicines could provide an important tool for pharmaceutical policy evaluation: –Serve as a retrospective policy evaluator for decision-makers ( interrupted time series) –Serve as a prospective means to monitor policy impact in each country (trend analysis).